About the journal
Journal of Drug Assessment is a journal published by Taylor & Francis in United Kingdom. It is listed in PUBMED according to the sources read. Declared publication charge: 969 GBP. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Taylor & Francis
- ISSN
- 2155-6660
- Country
- United Kingdom
- Access
- Not open access / not declared
- Declared publication charge
- 969 GBP
- Declared peer-review model
- peer_review
- Official website
- https://www.tandfonline.com/toc/ijda20/current
Index listings
- PUBMED · 2020-07-23
- Indexing
- PUBMED
- APC
- 969 GBP
- Declared review time (DOAJ)
- —
- Activity (OpenAlex)
- Active — latest works 2023
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
202
Last recorded publication year
2022
h-index
25
i10-index
62
From OpenAlex open data (CC0).
Editorial & policy3
- Observed digital preservation (Keepers registry)— snapshot 2026-09-21
- CLOCKSSPortico
- Open references deposited at Crossref
- 0%
- ORCID iDs in current deposits
- 0%
Identity & continuity2
- Alternate titles
- JDA
- Source type
- journal
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Medication Adherence and Compliance
- Medication Adherence and Compliance
- Health Systems, Economic Evaluations, Quality of Life
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Pharmaceutical studies and practices
- Pharmaceutical Practices and Patient Outcomes
- Pharmaceutical Practices and Patient Outcomes
Show all subjects (50)
- Pharmaceutical Economics and Policy
- Pharmaceutical Economics and Policy
- Allergic Rhinitis and Sensitization
- Allergic Rhinitis and Sensitization
- Hepatitis C virus research
- Asthma and respiratory diseases
- Multiple Sclerosis Research Studies
- Economic and Financial Impacts of Cancer
- Economic and Financial Impacts of Cancer
- Diabetes Treatment and Management
- Multiple Sclerosis Research Studies
- Hepatitis C virus research
- Diabetes Treatment and Management
- Asthma and respiratory diseases
- Lipoproteins and Cardiovascular Health
- Lipoproteins and Cardiovascular Health
- Hemophilia Treatment and Research
- Hemophilia Treatment and Research
- Chronic Lymphocytic Leukemia Research
- HIV/AIDS drug development and treatment
- Chronic Lymphocytic Leukemia Research
- Pharmacogenetics and Drug Metabolism
- HIV/AIDS drug development and treatment
- Pharmacogenetics and Drug Metabolism
- Blood Pressure and Hypertension Studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes Management and Research
- Blood Pressure and Hypertension Studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Pharmaceutical industry and healthcare
- Pharmaceutical industry and healthcare
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Diabetes Management and Research
- HIV/AIDS Research and Interventions
- Inflammatory mediators and NSAID effects
- Inflammatory mediators and NSAID effects
- Heart Failure Treatment and Management
- HIV/AIDS Research and Interventions
- Bone health and osteoporosis research
- Heart Failure Treatment and Management
- Bone health and osteoporosis research
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ